CLINICAL TRIAL | the abstract

Principal Investigator: Dr. Jennifer Cather

A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess the safety, efficacy, and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA (Principal Investigator).

Cutaneous T-cell lymphoma is a rare lymphoma involving the skin, and it can present clinically similar to atopic dermatitis or psoriasis.  Two strengths of a topical gel are being tested for this rare condition.  Results are scheduled to publish in late 2020.

SOTA Formula Consideration Based on Data:

Lymphoma, psoriasis, and atopic dermatitis, patients also suffer from symptoms of itching, which are often inadequately controlled with traditional medications. Over 80% of patients with CTCL have itching that responds inadequately to oral medications such as antihistamines, antidepressants, or gabapentin. Learn more about the benefits of SOTA Sleep and Calm Tinctures and SOTA Rebound Topical for relief from painful itching.

Increased IL-31 is in the serum and skin of patients with CTCL.

Study dates: 2018